TY - JOUR
T1 - Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
AU - Corradini, P.
AU - Vitolo, U.
AU - Rambaldi, A.
AU - Miceli, R.
AU - Patriarca, F.
AU - Gallamini, A.
AU - Olivieri, A.
AU - Benedetti, F.
AU - Todeschini, G.
AU - Rossi, G.
AU - Salvi, F.
AU - Bruno, B.
AU - Baldini, L.
AU - Ferreri, A.
AU - Patti, C.
AU - Tarella, C.
AU - Pileri, S.
AU - Dodero, A.
PY - 2014
Y1 - 2014
N2 - Peripheral T-cell lymphomas (PTCLs) receiving conventional treatment have a poor clinical outcome. We conducted a phase II study to evaluate the feasibility and efficacy of chemo-immunotherapy in young (≤60 years old, Clin A study) and elderly (>60 and ≤75 years old, Clin B study) patients with newly diagnosed PTCL. Clin A patients (n=61) received two courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone)-21 with alemtuzumab (AL, 30 mg) followed by two courses of high-dose chemotherapy. On the basis of donor availability, patients in response received allogeneic (allo) or autologous (auto) stem cell transplantation (SCT). Clin B patients (n=25) received six courses of CHOP-21 and AL (10 mg). Clin A responding patients were 38 of 61 (62%) and received alloSCT (n=23) or autoSCT (n=14); one complete remission (CR) patient was not transplanted. At a median follow-up of 40 months, the 4-year overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) rates were 49, 44 and 65%, respectively. In Clin B study, the response rate was 72%. At a median follow-up of 48 months, the 4-year OS, PFS and DFS rates were 31, 26 and 44%, respectively. In conclusion, front-line alloSCT or autoSCT is effective in prolonging DFS in young patients; AL in elderly improved response with no survival benefit.
AB - Peripheral T-cell lymphomas (PTCLs) receiving conventional treatment have a poor clinical outcome. We conducted a phase II study to evaluate the feasibility and efficacy of chemo-immunotherapy in young (≤60 years old, Clin A study) and elderly (>60 and ≤75 years old, Clin B study) patients with newly diagnosed PTCL. Clin A patients (n=61) received two courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone)-21 with alemtuzumab (AL, 30 mg) followed by two courses of high-dose chemotherapy. On the basis of donor availability, patients in response received allogeneic (allo) or autologous (auto) stem cell transplantation (SCT). Clin B patients (n=25) received six courses of CHOP-21 and AL (10 mg). Clin A responding patients were 38 of 61 (62%) and received alloSCT (n=23) or autoSCT (n=14); one complete remission (CR) patient was not transplanted. At a median follow-up of 40 months, the 4-year overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) rates were 49, 44 and 65%, respectively. In Clin B study, the response rate was 72%. At a median follow-up of 48 months, the 4-year OS, PFS and DFS rates were 31, 26 and 44%, respectively. In conclusion, front-line alloSCT or autoSCT is effective in prolonging DFS in young patients; AL in elderly improved response with no survival benefit.
UR - http://www.scopus.com/inward/record.url?scp=84908319588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908319588&partnerID=8YFLogxK
U2 - 10.1038/leu.2014.79
DO - 10.1038/leu.2014.79
M3 - Article
C2 - 24662801
AN - SCOPUS:84908319588
VL - 28
SP - 1885
EP - 1891
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 9
ER -